We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Off-label prescribing of medications for pain: maintaining optimal care at an intersection of law, public policy, and ethics.
- Authors
Ruble, James
- Abstract
For more than 60 years, regulations limited marketing of medications for off-label uses to very low levels. Some key policy changes in the late 1990s ushered in an era of deregulation of off-label marketing. Policy changes included revised United States federal law as well as modifications of Food and Drug Administration (FDA) regulations. Subsequent investigations documented an explosion in scope off-label prescribing. Attempts to limit off-label advertising by manufacturers were vigorously challenged in the courts. Other modalities are needed to maintain a clinical care environment that places the patients' best interests first. In many circumstances, an off-label medication may be in the patient's best interests; however, where there is a lower level of clinical justification, the informed consent of the patient and shared decision making of the patient is essential to optimize outcome.
- Publication
Journal of pain & palliative care pharmacotherapy, 2012, Vol 26, Issue 2, p146
- ISSN
1536-0539
- Publication type
Journal Article
- DOI
10.3109/15360288.2012.671243